DNA vaccination and gene therapy: optimization and delivery for cancer therapy

References

• Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet371(9614), 771–783 (2008).
   PubMed Web of Science ®Google Scholar
• van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science254(5038), 1643–1647 (1991).
   PubMed Web of Science ®Google Scholar
• Beyer M, Schultze JL. Immunoregulatory T cells: role and potential as a target in malignancy. Curr. Oncol. Rep.10(2), 130–136 (2008).
   PubMed Web of Science ®Google Scholar
• Rescigno M, Avogadri F, Curigliano G. Challenges and prospects of immunotherapy as cancer treatment. Biochim. Biophys. Acta1776(1), 108–123 (2007).
   PubMed Web of Science ®Google Scholar
• Prud’homme GJ. DNA vaccination against tumors. J. Gene Med.7(1), 3–17 (2005).
   PubMed Web of Science ®Google Scholar
• Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat. Rev. Cancer8(2), 108–120 (2008).
   PubMed Web of Science ®Google Scholar
• Marshall J. Carcinoembryonic antigen-based vaccines. Semin. Oncol.30(3 Suppl. 8), 30–36 (2003).
   PubMed Web of Science ®Google Scholar
• Renard V, Leach DR. Perspectives on the development of a therapeutic HER-2 cancer vaccine. Vaccine25(Suppl. 2), B17–B23 (2007).
   PubMedGoogle Scholar
• Park JM, Terabe M, Steel JC et al. Therapy of advanced established murine breast cancer with a recombinant adenoviral ErbB-2/neu vaccine. Cancer Res.68(6), 1979–1987 (2008).
   PubMed Web of Science ®Google Scholar
• Curcio C, Khan AS, Amici A et al. DNA immunization using constant-current electroporation affords long-term protection from autochthonous mammary carcinomas in cancer-prone transgenic mice. Cancer Gene Ther.15(2), 108–114 (2008).
   PubMedGoogle Scholar
• Atallah E, Flaherty L. Treatment of metastatic malignant melanoma. Curr. Treat. Options Oncol.6(3), 185–193 (2005).
   PubMedGoogle Scholar
• Agostino NM, Ali A, Nair SG, Mosca PJ. Current immunotherapeutic strategies in malignant melanoma. Surg. Oncol. Clin. N. Am.16(4), 945–973, xi (2007).
   Google Scholar
• Vujanovic L, Butterfield LH. Melanoma cancer vaccines and anti-tumor T cell responses. J. Cell. Biochem.102(2), 301–310 (2007).
   PubMed Web of Science ®Google Scholar
• Wagner E. Advances in cancer gene therapy: tumor-targeted delivery of therapeutic pDNA, siRNA, and dsRNA nucleic acids. J. BUON12(Suppl. 1), S77–S82 (2007).
   PubMedGoogle Scholar
• Jechlinger W. Optimization and delivery of plasmid DNA for vaccination. Expert Rev. Vaccines5(6), 803–825 (2006).
   PubMed Web of Science ®Google Scholar
• Li X, Eastman EM, Schwartz RJ, Draghia-Akli R. Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences. Nat. Biotechnol.17(3), 241–245 (1999).
   PubMed Web of Science ®Google Scholar
• Wright A, Semyonov A, Dawes G et al. Diverse plasmid DNA vectors by directed molecular evolution of cytomegalovirus promoters. Hum. Gene Ther.16(7), 881–892 (2005).
   PubMed Web of Science ®Google Scholar
• Chen P, Tian J, Kovesdi I, Bruder JT. Promoters influence the kinetics of transgene expression following adenovector gene delivery. J. Gene Med.10(2), 123–131 (2008).
   Google Scholar
• Tai CK, Kasahara N. Replication-competent retrovirus vectors for cancer gene therapy. Front. Biosci.13, 3083–3095 (2008).
   PubMed Web of Science ®Google Scholar
• Wierstra I, Alves J. The c-myc promoter: still MysterY and challenge. Adv. Cancer Res.99, 113–333 (2008).
   PubMedGoogle Scholar
• Kelly BJ, Fleeton MN, Atkins GJ. Potential of alphavirus vectors in the treatment of advanced solid tumors. Recent Patents Anticancer Drug Discov.2(2), 159–166 (2007).
   Google Scholar
• Chen JS, Liu JC, Shen L et al. Cancer-specific activation of the survivin promoter and its potential use in gene therapy. Cancer Gene Ther.11(11), 740–747 (2004).
   PubMedGoogle Scholar
• Lu B, Makhija SK, Nettelbeck DM et al. Evaluation of tumor-specific promoter activities in melanoma. Gene Ther.12(4), 330–338 (2005).
   PubMed Web of Science ®Google Scholar
• Bodles-Brakhop AM, Brown PA, Pope MA, Draghia-Akli R. Double-blinded, placebo-controlled plasmid GHRH trial for cancer-associated anemia in dogs. Mol. Ther.16(5), 862–870 (2008).
   Google Scholar
• Draghia-Akli R, Hahn KA, King GK, Cummings K, Carpenter RH. Effects of plasmid mediated growth hormone releasing hormone in severely debilitated dogs with cancer. Mol. Ther.6(6), 830–836 (2002).
   PubMed Web of Science ®Google Scholar
• Yan J, Harris K, Khan AS, Draghia-Akli R, Sewell DA, Weiner DB. Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques. Vaccine (2008) DOI: 10.1016/j.vaccine.2008.03.069 (Epub ahead of print).
   Google Scholar
• Tone CM, Cardoza DM, Carpenter RH, Draghia-Akli R. Long-term effects of plasmid-mediated growth hormone releasing hormone in dogs. Cancer Gene Ther.11(5), 389–396 (2004).
   PubMed Web of Science ®Google Scholar
• Narisawa-Saito M, Kiyono T. Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Sci.98(10), 1505–1511 (2007).
   PubMed Web of Science ®Google Scholar
• Disbrow GL, Sunitha I, Baker CC, Hanover J, Schlegel R. Codon optimization of the HPV-16 E5 gene enhances protein expression. Virology311(1), 105–114 (2003).
   PubMed Web of Science ®Google Scholar
• Cid-Arregui A, Juarez V, zur Hausen H. A synthetic E7 gene of human papillomavirus type 16 that yields enhanced expression of the protein in mammalian cells and is useful for DNA immunization studies. J. Virol.77(8), 4928–4937 (2003).
   PubMed Web of Science ®Google Scholar
• Cheung YK, Cheng SC, Sin FW, Xie Y. Plasmid encoding papillomavirus type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection. Vaccine23(5), 629–638 (2004).
   PubMed Web of Science ®Google Scholar
• Kim MS, Sin JI. Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model. Immunology116(2), 255–266 (2005).
   PubMed Web of Science ®Google Scholar
• Ahmed A, Thompson J, Emiliusen L et al. A conditionally replicating adenovirus targeted to tumor cells through activated RAS/P-MAPK-selective mRNA stabilization. Nat. Biotechnol.21(7), 771–777 (2003).
   PubMed Web of Science ®Google Scholar
• Hirao L, Wu L, Khan AS et al. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques. Vaccine26(25), 3112–3120 (2008).
   PubMed Web of Science ®Google Scholar
• Draghia-Akli R, Pope MA, Brown PA, Khan AS. Plasmid-based expression technology using growth hormone releasing hormone: a novel method for physiologically stimulating long-term growth hormone secretion. Comb. Chem. High Throughput Screen9(3), 181–185 (2006).
   Google Scholar
• Kumagai Y, Takeuchi O, Akira S. TLR9 as a key receptor for the recognition of DNA. Adv. Drug Deliv. Rev.60(7), 795–804 (2008).
   PubMed Web of Science ®Google Scholar
• Verthelyi D. Adjuvant properties of CpG oligonucleotides in primates. Methods Mol. Med.127, 139–158 (2006).
   Google Scholar
• McCluskie MJ, Weeratna RD, Davis HL. The role of CpG in DNA vaccines. Springer Semin. Immunopathol.22(1–2), 125–132 (2000).
   PubMed Web of Science ®Google Scholar
• Schneeberger A, Wagner C, Zemann A et al. CpG motifs are efficient adjuvants for DNA cancer vaccines. J. Invest. Dermatol.123(2), 371–379 (2004).
   PubMed Web of Science ®Google Scholar
• Bertin S, Anjuere F, Gavelli A et al. Plasmidic CpG sequences induce tumor microenvironment modifications in a rat liver metastasis model. Int. J. Mol. Med.21(3), 309–315 (2008).
   Google Scholar
• Coban C, Ishii KJ, Gursel M, Klinman DM, Kumar N. Effect of plasmid backbone modification by different human CpG motifs on the immunogenicity of DNA vaccine vectors. J. Leukoc. Biol.78(3), 647–655 (2005).
   PubMed Web of Science ®Google Scholar
• Raykov Z, Grekova S, Leuchs B, Aprahamian M, Rommelaere J. Arming parvoviruses with CpG motifs to improve their oncosuppressive capacity. Int. J. Cancer122(12), 2880–2884 (2008).
   PubMed Web of Science ®Google Scholar
• Bequet-Romero M, Ayala M, Acevedo BE et al. Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice. Angiogenesis10(1), 23–34 (2007).
   PubMedGoogle Scholar
• Murad YM, Clay TM, Lyerly HK, Morse MA. CPG-7909 (PF-3512676, ProMune): Toll-like receptor-9 agonist in cancer therapy. Expert Opin. Biol. Ther.7(8), 1257–1266 (2007).
   PubMed Web of Science ®Google Scholar
• Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol.6(8), 595–601 (2006).
   PubMed Web of Science ®Google Scholar
• Cheng WF, Chang MC, Sun WZ et al. Connective tissue growth factor linked to the E7 tumor antigen generates potent antitumor immune responses mediated by an antiapoptotic mechanism. Gene Ther.15(13), 1007–1016 (2008).
   Google Scholar
• Hsieh CY, Chen CA, Huang CY et al. IL-6-encoding tumor antigen generates potent cancer immunotherapy through antigen processing and anti-apoptotic pathways. Mol. Ther.15(10), 1890–1897 (2007).
   PubMedGoogle Scholar
• Ferrone CR, Perales MA, Goldberg SM et al. Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains. Clin. Cancer Res.12(18), 5511–5519 (2006).
   PubMed Web of Science ®Google Scholar
• Qin H, Zhou C, Wang D et al. Enhancement of antitumour immunity by a novel chemotactic antigen DNA vaccine encoding chemokines and multiepitopes of prostate-tumour-associated antigens. Immunology117(3), 419–430 (2006).
   Google Scholar
• Lin CT, Tsai YC, He L et al. DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity. Immunol.Lett.114(2), 86–93 (2007).
   PubMed Web of Science ®Google Scholar
• Snyder LA, Goletz TJ, Gunn GR et al. A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice. Vaccine24(16), 3340–3352 (2006).
   PubMed Web of Science ®Google Scholar
• Marshall DJ, Rudnick KA, McCarthy SG et al. Interleukin-18 enhances Th1 immunity and tumor protection of a DNA vaccine. Vaccine24(3), 244–253 (2006).
   PubMed Web of Science ®Google Scholar
• Yang TC, Millar JB, Grinshtein N, Bassett J, Finn J, Bramson JL. T-cell immunity generated by recombinant adenovirus vaccines. Expert Rev. Vaccines6(3), 347–356 (2007).
   PubMed Web of Science ®Google Scholar
• Yang ZR, Wang HF, Zhao J et al. Recent developments in the use of adenoviruses and immunotoxins in cancer gene therapy. Cancer Gene Ther.14(7), 599–615 (2007).
   PubMed Web of Science ®Google Scholar
• Park K, Kim WJ, Cho YH et al. Cancer gene therapy using adeno-associated virus vectors. Front Biosci.13, 2653–2659 (2008).
   PubMed Web of Science ®Google Scholar
• Li C, Bowles DE, van DT, Samulski RJ. Adeno-associated virus vectors: potential applications for cancer gene therapy. Cancer Gene Ther.12(12), 913–925 (2005).
   PubMed Web of Science ®Google Scholar
• Coura RS, Nardi NB. The state of the art of adeno-associated virus-based vectors in gene therapy. Virol. J.4, 99 (2007).
   PubMed Web of Science ®Google Scholar
• Hedley SJ, Chen J, Mountz JD et al. Targeted and shielded adenovectors for cancer therapy. Cancer Immunol.Immunother.55(11), 1412–1419 (2006).
   PubMed Web of Science ®Google Scholar
• Zhu ZB, Rivera AA, Makhija SK et al. Targeting lung cancer using an infectivity enhanced CXCR4-CRAd. Lung Cancer55(2), 145–156 (2007).
   Google Scholar
• Zhu ZB, Chen Y, Makhija SK et al. Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma. Int. J. Oncol.29(5), 1319–1329 (2006).
   Google Scholar
• Egami T, Ohuchida K, Mizumoto K et al. Radiation enhances adenoviral gene therapy in pancreatic cancer via activation of cytomegalovirus promoter and increased adenovirus uptake. Clin.Cancer Res.14(6), 1859–1867 (2008).
   PubMed Web of Science ®Google Scholar
• Hartman ZC, Appledorn DM, Amalfitano A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res.132(1–2), 1–14 (2008).
   PubMed Web of Science ®Google Scholar
• Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J. Exp.Med.205(1), 7–12 (2008).
   PubMed Web of Science ®Google Scholar
• Pandha HS, Martin LA, Rigg A et al. Genetic prodrug activation therapy for breast cancer: a Phase I clinical trial of erbB-2-directed suicide gene expression. J. Clin.Oncol.17(7), 2180–2189 (1999).
   PubMed Web of Science ®Google Scholar
• Heller LC, Ugen K, Heller R. Electroporation for targeted gene transfer. Expert. Opin. Drug Deliv.2(2), 255–268 (2005).
   PubMedGoogle Scholar
• Heller LC, Heller R. In vivo electroporation for gene therapy. Hum. Gene Ther.17(9), 890–897 (2006).
   PubMed Web of Science ®Google Scholar
• Cemazar M, Sersa G. Electrotransfer of therapeutic molecules into tissues. Curr.Opin. Mol .Ther.9(6), 554–562 (2007).
   PubMedGoogle Scholar
• Cemazar M, Golzio M, Sersa G, Rols MP, Teissie J. Electrically-assisted nucleic acids delivery to tissues in vivo: where do we stand? Curr. Pharm. Des.12(29), 3817–3825 (2006).
   PubMed Web of Science ®Google Scholar
• Laddy DJ, Yan J, Kutzler M et al. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS ONE3(6), e2517 (2008).
   PubMed Web of Science ®Google Scholar
• Rosati M, Valentin A, Jalah R et al. Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine DOI: 10.1016/j.vaccine.2008.03.090 (2008) [Epub ahead of print].
   Google Scholar
• Keegan ME, Saltzman WM. Surface-modified biodegradable microspheres for DNA vaccine delivery. Methods Mol. Med.127, 107–113 (2006).
   PubMedGoogle Scholar
• Mahato RI. Water insoluble and soluble lipids for gene delivery. Adv. Drug Deliv. Rev.57(5), 699–712 (2005).
   PubMed Web of Science ®Google Scholar
• Lv H, Zhang S, Wang B, Cui S, Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Release114(1), 100–109 (2006).
   PubMed Web of Science ®Google Scholar
• Tang CK, Lodding J, Minigo G et al. Mannan-mediated gene delivery for cancer immunotherapy. Immunology120(3), 325–335 (2007).
   Google Scholar
• Hartikka J, Geall A, Bozoukova V et al. Physical characterization and evaluation of poloxamer-based DNA vaccine formulations. J. Gene Med.10, 770–782 (2008).
   PubMed Web of Science ®Google Scholar
• Neumann E, Schaefer-Ridder M, Wang Y, Hofschneider PH. Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J.1(7), 841–845 (1982).
   PubMed Web of Science ®Google Scholar
• Draghia-Akli R, Khan AS, Brown PA et al. Parameters for DNA vaccination using adaptive constant-current electroporation in mouse and pig models. Vaccine DOI: 10.1016/j.vaccine.2008.03.071 (2008) [Epub ahead of print].
   Google Scholar
• Khan AS, Pope MA, Draghia-Akli R. Highly efficient constant-current electroporation increases in vivo plasmid expression. DNA Cell Biol.24(12), 810–818 (2005).
   PubMed Web of Science ®Google Scholar
• Cemazar M, Pavlin D, Kranjc S, Grosel A, Mesojednik S, Sersa G. Sequence and time dependence of transfection efficiency of electrically-assisted gene delivery to tumors in mice. Curr. Drug Deliv.3(1), 77–81 (2006).
   PubMedGoogle Scholar
• Mesojednik S, Pavlin D, Sersa G et al. The effect of the histological properties of tumors on transfection efficiency of electrically assisted gene delivery to solid tumors in mice. Gene Ther.14, 1261–1269 (2007).
   Google Scholar
• Kalat M, Kupcu Z, Schuller S et al.In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model. Cancer Res.62(19), 5489–5494 (2002).
   PubMed Web of Science ®Google Scholar
• Buchan S, Gronevik E, Mathiesen I, King CA, Stevenson FK, Rice J. Electroporation as a ‘prime/boost’ strategy for naked DNA vaccination against a tumor antigen. J. Immunol.174(10), 6292–6298 (2005).
   PubMed Web of Science ®Google Scholar
• Roos AK, Moreno S, Leder C, Pavlenko M, King A, Pisa P. Enhancement of cellular immune response to a prostate cancer DNA vaccine by intradermal electroporation. Mol. Ther.13(2), 320–327 (2006).
   PubMed Web of Science ®Google Scholar
• Fredriksen AB, Sandlie I, Bogen B. DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells. Mol. Ther.13(4), 776–785 (2006).
   PubMedGoogle Scholar
• Manome Y, Nakamura M, Ohno T, Furuhata H. Ultrasound facilitates transduction of naked plasmid DNA into colon carcinoma cells in vitro and in vivo. Hum. Gene Ther.11(11), 1521–1528 (2000).
   PubMed Web of Science ®Google Scholar
• Dittmar KM, Xie J, Hunter F et al. Pulsed high-intensity focused ultrasound enhances systemic administration of naked DNA in squamous cell carcinoma model: initial experience. Radiology235(2), 541–546 (2005).
   PubMed Web of Science ®Google Scholar
• Kusumanto YH, Mulder NH, Dam WA, Losen MH, Meijer C, Hospers GA. Improvement of in vivo transfer of plasmid DNA in muscle: comparison of electroporation versus ultrasound. Drug Deliv.14(5), 273–277 (2007).
   PubMed Web of Science ®Google Scholar
• Rakhmilevich AL, Turner J, Ford MJ et al. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc. Natl Acad. Sci. USA93(13), 6291–6296 (1996).
   PubMed Web of Science ®Google Scholar
• Oshikawa K, Ishii Y, Hamamoto T, Sugiyama Y, Kitamura S, Kagawa Y. Particle-mediated gene transfer of murine interleukin-12 cDNA suppresses the growth of Lewis lung carcinoma. In Vivo13(5), 397–402 (1999).
   Google Scholar
• Cassaday RD, Sondel PM, King DM et al. A Phase I study of immunization using particle-mediated epidermal delivery of genes for gp100 and GM-CSF into uninvolved skin of melanoma patients. Clin. Cancer Res.13(2 Pt 1), 540–549 (2007).
   PubMed Web of Science ®Google Scholar
• Sharma R, Sharma CL. Quadrivalent human papillomavirus recombinant vaccine: the first vaccine for cervical cancers. J. Cancer Res. Ther.3(2), 92–95 (2007).
   Google Scholar
• Hoos A, Parmiani G, Hege K et al. A clinical development paradigm for cancer vaccines and related biologics. J. Immunother.30(1), 1–15 (2007).
   PubMed Web of Science ®Google Scholar
• Bergman PJ, Camps-Palau MA, McKnight JA et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine24(21), 4582–4585 (2006).
   PubMed Web of Science ®Google Scholar
• Bergman PJ, McKnight J, Novosad A et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a Phase I trial. Clin. Cancer Res.9(4), 1284–1290 (2003).
   PubMed Web of Science ®Google Scholar
• Liao JC, Gregor P, Wolchok JD et al. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun.6, 8 (2006).
   PubMedGoogle Scholar
• Muscaritoli M, Bossola M, Aversa Z, Bellantone R, Rossi FF. Prevention and treatment of cancer cachexia: new insights into an old problem. Eur. J. Cancer42(1), 31–41 (2006).
   PubMed Web of Science ®Google Scholar
• Veldhuis JD, Iranmanesh A, Weltman A. Elements in the pathophysiology of diminished growth hormone (GH) secretion in aging humans. Endocrine7(1), 41–48 (1997).
   PubMed Web of Science ®Google Scholar
• Ekenstedt KJ, Sonntag WE, Loeser RF, Lindgren BR, Carlson CS. Effects of chronic growth hormone and insulin-like growth factor 1 deficiency on osteoarthritis severity in rat knee joints. Arthritis Rheum.54(12), 3850–3858 (2006).
   PubMed Web of Science ®Google Scholar
• Khan AS, Anscombe IW, Cummings KK, Pope MA, Smith LC, Draghia-Akli R. Growth hormone releasing hormone plasmid supplementation, a potential treatment for cancer cachexia, does not increase tumor growth in nude mice. Cancer Gene Ther.12(1), 54–60 (2005).
   PubMedGoogle Scholar
• Jorritsma A, Bins AD, Schumacher TN, Haanen JB. Skewing the T-cell repertoire by combined DNA vaccination, host conditioning, and adoptive transfer. Cancer Res.68(7), 2455–2462 (2008).
   Google Scholar
• Garcia-Hernandez ML, Gray A, Hubby B, Klinger OJ, Kast WM. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res.68(3), 861–869 (2008).
   PubMed Web of Science ®Google Scholar
• Steinaa L, Rasmussen PB, Gautam A, Mouritsen S. Breaking B-cell tolerance and CTL tolerance in three OVA-transgenic mouse strains expressing different levels of OVA. Scand. J. Immunol.67(2), 113–120 (2008).
   Google Scholar
• Jeon YH, Choi Y, Kim HJ et al.In vivo bioluminescence visualization of antitumor effects by human MUC1 vaccination. Mol. Imaging6(5), 297–303 (2007).
   Google Scholar
• Wang YS, Wang GQ, Wen YJ et al. Immunity against tumor angiogenesis induced by a fusion vaccine with murine β-defensin 2 and mFlk-1. Clin. Cancer Res.13(22 Pt 1), 6779–6787 (2007).
   PubMedGoogle Scholar
• Mkrtichyan M, Ghochikyan A, Loukinov D et al. DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice. Gene Ther.15(1), 61–64 (2008).
   PubMedGoogle Scholar
• Bos R, van DS, van HT et al. Characterization of antigen-specific immune responses induced by canarypox virus vaccines. J. Immunol.179(9), 6115–6122 (2007).
   PubMedGoogle Scholar
• Orlandi F, Venanzi FM, Concetti A et al. Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine. Clin. Cancer Res.13(20), 6195–6203 (2007).
   Google Scholar
• Kim D, Hoory T, Wu TC, Hung CF. Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life and intracellular targeting strategies with a strategy to boost CD4+ T cells. Hum. Gene Ther.18(11), 1129–1139 (2007).
   Google Scholar
• Zhu K, Qin H, Cha SC et al. Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. Vaccine25(46), 7955–7961 (2007).
   Google Scholar
• Huang CY, Chen CA, Lee CN et al. DNA vaccine encoding heat shock protein 60 co-linked to HPV16 E6 and E7 tumor antigens generates more potent immunotherapeutic effects than respective E6 or E7 tumor antigens. Gynecol. Oncol.107(3), 404–412 (2007).
   PubMed Web of Science ®Google Scholar
• Yo YT, Hsu KF, Shieh GS et al. Coexpression of Flt3 ligand and GM-CSF genes modulates immune responses induced by HER2/neu DNA vaccine. Cancer Gene Ther.14(11), 904–917 (2007).
   Google Scholar
• Oh S, Pluhar GE, McNeil EA et al. Efficacy of nonviral gene transfer in the canine brain. J. Neurosurg.107(1), 136–144 (2007).
   PubMed Web of Science ®Google Scholar
• Scardino A, Alimandi M, Correale P et al. A polyepitope DNA vaccine targeted to Her-2/ErbB-2 elicits a broad range of human and murine CTL effectors to protect against tumor challenge. Cancer Res.67(14), 7028–7036 (2007).
   PubMedGoogle Scholar